BE2017C009I2 - - Google Patents
Info
- Publication number
- BE2017C009I2 BE2017C009I2 BE2017C009C BE2017C009C BE2017C009I2 BE 2017C009 I2 BE2017C009 I2 BE 2017C009I2 BE 2017C009 C BE2017C009 C BE 2017C009C BE 2017C009 C BE2017C009 C BE 2017C009C BE 2017C009 I2 BE2017C009 I2 BE 2017C009I2
- Authority
- BE
- Belgium
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Gynecology & Obstetrics (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pregnancy & Childbirth (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55008200A | 2000-04-14 | 2000-04-14 | |
| US09/748,960 US20010046496A1 (en) | 2000-04-14 | 2000-12-27 | Method of administering an antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE2017C009I2 true BE2017C009I2 (OSRAM) | 2017-09-22 |
Family
ID=27069332
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE2017C009C BE2017C009I2 (OSRAM) | 2000-04-14 | 2017-04-11 |
Country Status (15)
| Country | Link |
|---|---|
| US (5) | US20010046496A1 (OSRAM) |
| EP (3) | EP3167902B1 (OSRAM) |
| JP (3) | JP2003531129A (OSRAM) |
| AU (1) | AU2001251629A1 (OSRAM) |
| BE (1) | BE2017C009I2 (OSRAM) |
| CA (1) | CA2406220C (OSRAM) |
| CY (3) | CY1113489T1 (OSRAM) |
| DK (2) | DK2298348T3 (OSRAM) |
| ES (2) | ES2609689T3 (OSRAM) |
| FR (1) | FR14C0080I2 (OSRAM) |
| LU (1) | LUC00014I2 (OSRAM) |
| MX (1) | MXPA02010059A (OSRAM) |
| NL (1) | NL300702I1 (OSRAM) |
| PT (1) | PT2298348T (OSRAM) |
| WO (1) | WO2001078779A2 (OSRAM) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7521053B2 (en) | 2001-10-11 | 2009-04-21 | Amgen Inc. | Angiopoietin-2 specific binding agents |
| US7658924B2 (en) * | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
| EP3674322A1 (en) * | 2002-02-25 | 2020-07-01 | Biogen MA Inc. | Administration of agents for the treatment of inflammation |
| GB0210121D0 (en) * | 2002-05-02 | 2002-06-12 | Celltech R&D Ltd | Biological products |
| HUE057124T2 (hu) | 2002-05-02 | 2022-04-28 | Wyeth Holdings Llc | Calicheamicin származék - hordozó konjugátumok |
| PE20051053A1 (es) * | 2004-01-09 | 2005-12-12 | Pfizer | ANTICUERPOS CONTRA MAdCAM |
| EP2322556B1 (en) * | 2004-09-03 | 2015-10-21 | Genentech, Inc. | Humanized anti-beta7 antagonists and uses therefor |
| EP1904531B1 (en) * | 2005-07-08 | 2010-10-06 | Pfizer Limited | Madcam antibodies |
| WO2007007152A2 (en) * | 2005-07-11 | 2007-01-18 | Pfizer Limited | Anti-madcam antibodies to treat metastatic cancers and chloroma |
| MX2008000659A (es) * | 2005-07-11 | 2008-03-13 | Pfizer Ltd | Nueva combinacion de anticuerpo contra madcam y de inhibidor de caspasa antifibrotico. |
| EP2109460B1 (en) | 2007-01-11 | 2016-05-18 | Novo Nordisk A/S | Anti-kir antibodies, formulations, and uses thereof |
| JP2010521966A (ja) * | 2007-03-20 | 2010-07-01 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | α４β７インテグリンに結合するヒト化免疫グロブリンをコードする核酸 |
| US20110105724A1 (en) * | 2007-08-16 | 2011-05-05 | Stephanie Jane Clegg | Novel compounds |
| JO2913B1 (en) | 2008-02-20 | 2015-09-15 | امجين إنك, | Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses |
| KR101361905B1 (ko) * | 2008-05-16 | 2014-02-21 | 제넨테크, 인크. | 베타7 인테그린 길항제를 이용한 위장관 염증 장애의 치료를 평가하기 위한 바이오마커의 용도 |
| KR101346530B1 (ko) | 2009-03-20 | 2013-12-31 | 암젠 인크 | 알파-4-베타-7 이종이량체 특이적 길항제 항체 |
| EP3578205A1 (en) | 2010-08-06 | 2019-12-11 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
| CN103429606A (zh) | 2010-10-01 | 2013-12-04 | 现代治疗公司 | 设计核酸及其使用方法 |
| CA2831613A1 (en) | 2011-03-31 | 2012-10-04 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| UA116189C2 (uk) * | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| US10040855B2 (en) | 2011-05-02 | 2018-08-07 | Millennium Pharmaceuticals, Inc. | Formulation for anti-α4β7 antibody |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| KR20190099538A (ko) | 2011-10-03 | 2019-08-27 | 모더나 세라퓨틱스, 인코포레이티드 | 변형된 뉴클레오사이드, 뉴클레오타이드, 및 핵산, 및 이들의 용도 |
| WO2013078375A2 (en) * | 2011-11-23 | 2013-05-30 | Amgen Inc. | Administration of alpha4beta7 hetero-dimer-specific antibody |
| EP4144378A1 (en) | 2011-12-16 | 2023-03-08 | ModernaTX, Inc. | Modified nucleoside, nucleotide, and nucleic acid compositions |
| EA034583B1 (ru) * | 2012-01-12 | 2020-02-21 | Милленниум Фармасьютикалз, Инк. | ПРИМЕНЕНИЯ АНТИ-α4β7 АНТИТЕЛА |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| AU2013243954A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| DK2922554T3 (en) | 2012-11-26 | 2022-05-23 | Modernatx Inc | Terminalt modificeret rna |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| BR112016007255A2 (pt) | 2013-10-03 | 2017-09-12 | Moderna Therapeutics Inc | polinucleotídeos que codificam receptor de lipoproteína de baixa densidade |
| EP3581585A1 (en) | 2014-11-26 | 2019-12-18 | Millennium Pharmaceuticals, Inc. | Vedolizumab for the treatment of fistulizing crohn's disease |
| US20170360926A1 (en) | 2014-12-24 | 2017-12-21 | Millennium Pharmaceuticals, Inc. | PREDICTING OUTCOME OF TREATMENT WITH AN ANTI-alpha4beta7 INTEGRIN ANTIBODY |
| CN109153721A (zh) | 2016-03-14 | 2019-01-04 | 千禧制药公司 | 治疗或预防移植物抗宿主疾病的方法 |
| BR112018068628A2 (pt) | 2016-03-14 | 2019-07-30 | Millennium Pharm Inc | método de prevenção de doença do enxerto contra hospedeiro |
| US11760803B2 (en) | 2016-03-24 | 2023-09-19 | Takeda Pharmaceutical Company Limited | Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments |
| TW201735949A (zh) | 2016-03-24 | 2017-10-16 | 千禧製藥公司 | 治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法 |
| JP7162533B2 (ja) | 2016-05-04 | 2022-10-28 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | 炎症性腸疾患の治療を目的とする三剤併用療法 |
| WO2017218434A1 (en) | 2016-06-12 | 2017-12-21 | Millennium Pharmaceuticals, Inc. | Method of treating inflammatory bowel disease |
| CR20200076A (es) | 2017-07-14 | 2020-06-10 | Pfizer | ANTICUERPOS CONTRA MAdCAM |
| US12492245B2 (en) * | 2021-09-21 | 2025-12-09 | University Of South Carolina | Anti-CCL8 antibodies and treatment of lung injury by CCL8 inhibition |
| WO2024249568A1 (en) | 2023-05-30 | 2024-12-05 | Paragon Therapeutics, Inc. | Alpha4beta7 integrin antibody compositions and methods of use |
| WO2024252368A2 (en) | 2023-06-09 | 2024-12-12 | Takeda Pharmaceutical Company Limited | Methods and compositions for treating ulcerative colitis |
| WO2025149974A1 (en) | 2024-01-11 | 2025-07-17 | Takeda Pharmaceutical Company Limited | Combination therapy with an anti-alpha4beta7 antibody |
| WO2025177214A1 (en) | 2024-02-20 | 2025-08-28 | Takeda Pharmaceutical Company Limited | Therapeutic methods |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4172124A (en) | 1978-04-28 | 1979-10-23 | The Wistar Institute | Method of producing tumor antibodies |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| ATE120761T1 (de) | 1987-05-21 | 1995-04-15 | Creative Biomolecules Inc | Multifunktionelle proteine mit vorbestimmter zielsetzung. |
| US5403919A (en) * | 1987-08-11 | 1995-04-04 | Board Of Trustees Of The Leland Stanford Junior University Stanford University | Method to control leukocyte extravasation |
| US5538724A (en) * | 1987-08-11 | 1996-07-23 | The Board Of Trustees For The Leland Stanford Junior Univ. | Method of control leukocyte extravasation |
| JP3095168B2 (ja) | 1988-02-05 | 2000-10-03 | エル． モリソン，シェリー | ドメイン‐変性不変部を有する抗体 |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| ATE356869T1 (de) | 1990-01-12 | 2007-04-15 | Amgen Fremont Inc | Bildung von xenogenen antikörpern |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| DE122004000008I1 (de) * | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| AU665025B2 (en) | 1991-09-23 | 1995-12-14 | Cambridge Antibody Technology Limited | Production of chimeric antibodies - a combinatorial approach |
| US5871734A (en) * | 1992-01-13 | 1999-02-16 | Biogen, Inc. | Treatment for asthma with VLA-4 blocking agents |
| US5932214A (en) * | 1994-08-11 | 1999-08-03 | Biogen, Inc. | Treatment for inflammatory bowel disease with VLA-4 blockers |
| DK0682529T4 (da) * | 1993-02-09 | 2006-05-15 | Biogen Idec Inc | Antistof til behandling af insulinkrævende diabetes |
| CA2115811A1 (en) | 1993-02-17 | 1994-08-18 | Claus Krebber | A method for in vivo selection of ligand-binding proteins |
| EP0714409A1 (en) | 1993-06-16 | 1996-06-05 | Celltech Therapeutics Limited | Antibodies |
| US5840299A (en) | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| GB2292079B (en) * | 1994-08-12 | 1998-07-15 | Flexpharm Ltd | Coated prednisolone preparation for the treatment of inflamatory bowel disease |
| US6551593B1 (en) * | 1995-02-10 | 2003-04-22 | Millennium Pharmaceuticals, Inc. | Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam |
| US6015662A (en) * | 1996-01-23 | 2000-01-18 | Abbott Laboratories | Reagents for use as calibrators and controls |
| US7147851B1 (en) * | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
| EP2314625B1 (en) | 1996-12-03 | 2014-05-07 | Amgen Fremont Inc. | Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom |
| HU229038B1 (hu) * | 1998-09-14 | 2013-07-29 | Regents Board Of | A mielóma multiplex és a mielóma indukált csontreszorpció kezelése integrin antagonistákkal |
-
2000
- 2000-12-27 US US09/748,960 patent/US20010046496A1/en not_active Abandoned
-
2001
- 2001-04-13 PT PT100109974T patent/PT2298348T/pt unknown
- 2001-04-13 JP JP2001576078A patent/JP2003531129A/ja not_active Withdrawn
- 2001-04-13 AU AU2001251629A patent/AU2001251629A1/en not_active Abandoned
- 2001-04-13 ES ES10010997.4T patent/ES2609689T3/es not_active Expired - Lifetime
- 2001-04-13 EP EP16191558.2A patent/EP3167902B1/en not_active Revoked
- 2001-04-13 ES ES01925028T patent/ES2398096T3/es not_active Expired - Lifetime
- 2001-04-13 MX MXPA02010059A patent/MXPA02010059A/es active IP Right Grant
- 2001-04-13 WO PCT/US2001/012234 patent/WO2001078779A2/en not_active Ceased
- 2001-04-13 EP EP01925028A patent/EP1278543B1/en not_active Expired - Lifetime
- 2001-04-13 DK DK10010997.4T patent/DK2298348T3/en active
- 2001-04-13 EP EP10010997.4A patent/EP2298348B9/en not_active Expired - Lifetime
- 2001-04-13 DK DK01925028.1T patent/DK1278543T3/da active
- 2001-04-13 CA CA2406220A patent/CA2406220C/en not_active Expired - Lifetime
-
2003
- 2003-12-15 US US10/735,863 patent/US20050095238A1/en not_active Abandoned
-
2011
- 2011-08-05 US US13/204,139 patent/US20120034243A1/en not_active Abandoned
-
2012
- 2012-05-02 JP JP2012105379A patent/JP5764524B2/ja not_active Expired - Lifetime
- 2012-12-18 CY CY20121101236T patent/CY1113489T1/el unknown
-
2014
- 2014-02-03 US US14/171,161 patent/US20140186345A1/en not_active Abandoned
- 2014-11-11 NL NL300702C patent/NL300702I1/nl unknown
- 2014-11-13 FR FR14C0080C patent/FR14C0080I2/fr active Active
- 2014-11-17 CY CY2014046C patent/CY2014046I1/el unknown
-
2015
- 2015-01-19 JP JP2015007655A patent/JP6021959B2/ja not_active Expired - Lifetime
-
2017
- 2017-01-05 CY CY20171100013T patent/CY1118429T1/el unknown
- 2017-04-11 LU LU00014C patent/LUC00014I2/fr unknown
- 2017-04-11 BE BE2017C009C patent/BE2017C009I2/nl unknown
-
2018
- 2018-11-02 US US16/179,157 patent/US20200002423A1/en not_active Abandoned